Analyst firms · Evercore ISI · EW
Evercore ISI EW price target and rating history
Edwards Lifesciences Corporation (EW) · Health Care
Evercore ISI rates Edwards Lifesciences Corporation (EW) Outperform with a $88 price target, as of its latest action on Oct 7, 2025. It has published 3 rating actions on EW since January 2022, including 1 upgrade and 1 downgrade. Across 7 firms with a EW price target in the last 12 months, the median target is $110.
- Current rating
- Outperform
- Price target
- $88
- Median target, all firms
- $110
- Actions on EW
- 3
Evercore ISI price target on EW
Every Evercore ISI rating on EW
- Oct 7, 2025
- Jan 4, 2024
- Jan 27, 2022
How other firms rate EW
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Robert W. Baird | Outperform | $116 | Nov 5, 2026 |
| Truist Securities | Buy | $113 | Nov 4, 2026 |
| Barclays | Overweight | $110 | Oct 7, 2026 |
| UBS | Buy | $110 | Jul 28, 2026 |
| Leerink Partners | Outperform | $101 | Jul 24, 2026 |
| Wolfe Research | Outperform | $92 | Apr 1, 2026 |
| TD Cowen | Buy | $97 | Jan 9, 2026 |
Questions about Evercore ISI and EW
- What is Evercore ISI's price target for EW?
- Evercore ISI's latest stated price target for Edwards Lifesciences Corporation (EW) is $88, from its action on Oct 7, 2025.
- What is Evercore ISI's rating on EW?
- Evercore ISI rates EW Outperform, a bullish rating, as of Oct 7, 2025.
- When did Evercore ISI last change its view on EW?
- On Oct 7, 2025, Evercore ISI upgrades to Outperform from In-line, price target $88.
- How does Evercore ISI's EW target compare with other analysts?
- Across 7 firms with a EW price target in the last 12 months, the median target is $110.
More EW rating histories
- Robert W. Baird3
- Truist Securities3
- UBS5
- Leerink Partners6
- Wolfe Research6
- Raymond James6
- Jefferies4
- Oppenheimer4
- Piper Sandler4
- Stifel4
- BofA Securities4
- Morgan Stanley6
- Citigroup4
- Wells Fargo6
- Credit Suisse3
All Evercore ISI ratingsEW news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.